CN105929176A - Kit for determining heart-type fatty acid binding protein and preparation method thereof - Google Patents
Kit for determining heart-type fatty acid binding protein and preparation method thereof Download PDFInfo
- Publication number
- CN105929176A CN105929176A CN201610358106.8A CN201610358106A CN105929176A CN 105929176 A CN105929176 A CN 105929176A CN 201610358106 A CN201610358106 A CN 201610358106A CN 105929176 A CN105929176 A CN 105929176A
- Authority
- CN
- China
- Prior art keywords
- reagent
- fatty acid
- binding protein
- acid binding
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kit for determining a heart-type fatty acid binding protein and a preparation method thereof. The kit comprises double-liquid components including a reagent R1 and a reagent R2 which are independent mutually, the reagent R1 is prepared from a buffer solution, a surface active agent, a chelating agent and a preservative, and the reagent R2 is prepared from a buffer solution, inorganic salt ions, a preservative, a stabilizer and a latex coated heart-type fatty acid binding protein antibody. The preparation method comprises the steps that the regents are prepared according to the contents of the components; a sample to be determined is mixed with the reagent R1 and the reagent R2; an absorbance difference value after reaction is determined by using a full-automatic biochemical analyzer; the concentration of the heart-type fatty acid binding protein in the sample is calculated according to an absorbance change value. The kit has the advantages of facilitating detection, being high in accuracy and the like.
Description
Technical field
The present invention relates to medical science and technological field of biochemistry, specifically a kind of mensuration cardic fatty acid binding protein
Kit and preparation method thereof.
Background technology
Cardic fatty acid binding protein (H-FABP) be in heart rich in the novel little cytoplasmic protein of one, it have height
Heartspecific, but the tissue beyond heart also has low concentration express, after myocardial ischemic injury occurs, H-FABP is permissible
Within 1-3 hour after episode, it is found in blood, within 6-8 hour, reaches peak value and blood plasma level is in 24-30 hour
Recovering normal, cardic fatty acid binding protein is made up of 132 amino acid, and molecular weight is 15 kDa, and cardioid aliphatic acid combines egg
(H-FABP) gene is positioned on chromosome I in vain, and it is heart one of rich in protein, cardic fatty acid binding protein (H-
FABP) combine two fatty acid molecules and participate in the transport of fatty acyl group coacetylase, being active in oxidizing process, thus at mitochondria
Middle generation energy.
The feature of cardic fatty acid binding protein (H-FABP) seems similar to myoglobins, and both is at cardiac muscle and bone
The low-molecular-weight cytoplasmic protein expressed in bone tissue is the matrix of mitochondrial oxidation and discharges in 2 hours after paresthesia epilepsy, 6
Hour Cmax occurs, in 24 hours, recover baseline concentrations, but, they are different with the concentration in musculature at heart,
In heart, H-FABP concentration is higher 2-10 times than in skeletal muscle, and in contrast, in heart cell, myoglobin concentration compares bone cells
In low 2 times, high 10-15 times than cardic fatty acid binding protein (H-FABP) of the normal plasma concentration of myoglobins, free blood
Slurry myoglobins level raises and is widely accepted early stage myocardial damage mark and demonstrates at Bhayana in 1994 et al.
Blood plasma myoglobins level raise than CK-MB and cTnT level raise after paresthesia epilepsy, 3-6 is little time interior eliminating Acute myocardial stalk
On plug (AMI), there is superiority.Although the early sign of heart injury is proposed as by myoglobins in the several criterions delivered
Thing, but cardic fatty acid binding protein (H-FABP) more has heartspecific and due to its possible quilt of its biological characteristics
It is considered one diagnostic test more accurately.
At present, the detection method of H-FABP has enzyme linked immunosorbent assay, radioimmunology etc., but these methods have limitation
Property, enzyme linked immunosorbent assay operation complexity, the longest, radioimmunology has radioactive element, has certain pollution to environment, and
And the measurement result degree of accuracy is low.
Summary of the invention
The technical problem to be solved is that prior art operation is complicated, pollute environment and measure accurate in order to overcome
The defect that exactness is low, and a kind of kit measuring cardic fatty acid binding protein and preparation method thereof is provided.
The technical scheme that the present invention solves above-mentioned technical problem and provides is: the invention discloses a kind of cardioid aliphatic acid that measures and ties
The kit of hop protein, including reagent R1 independent of each other and reagent R2 biliquid component, including composition and corresponding content be:
Reagent R1:
Buffer solution 15 ~ 185 mmol/L
Surfactant 5 ~ 15 mL/L
Chelating agent 10 ~ 60 mmol/L
Preservative 0.2 ~ 0.6 g/L
Its solvent is purified water
Reagent R2:
Buffer solution 50 ~ 150 mmol/L
Inorganic ion 40 ~ 300 mmol/L
Preservative 0.2 ~ 0.6 g/L
Stabilizer 6 ~ 18 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 1 ~ 8 g/L
Its solvent is purified water.
As preferably, the invention discloses a kind of kit measuring cardic fatty acid binding protein, including independently of one another
Reagent R1 and reagent R2 biliquid component, including composition and corresponding content be:
Reagent R1:
Buffer solution 100 mmol/L
Surfactant 10 mL/L
Chelating agent 35 mmol/L
Preservative 0.4 g/L
Its solvent is purified water
Reagent R2:
Buffer solution 100 mmol/L
Inorganic ion 200 mmol/L
Preservative 0.4g/L
Stabilizer 12 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 4 g/L
Its solvent is purified water.
As preferably, in described reagent R1, described buffer solution uses Tris buffer solution, MES buffer solution, MOPSO to delay
The combination of one or more in punching, glycine buffer, described surfactant uses Tween-20, described chelating agent
EDTA 2Na, described preservative is used to use the combination of one or more in Sodium azide, Proclin-300, phenol.
As preferably, in described reagent R2, described buffer solution uses Tris buffer solution, MES buffer solution, MOPSO to delay
One or more combinations in punching, glycine buffer, described inorganic ion uses in sodium chloride, magnesium chloride, potassium chloride
The combination of one or more, described preservative uses the group of one or more in Sodium azide, Proclin-300, phenol
Closing, described stabilizer uses the combination of one or more in sucrose, glycerine, bovine serum albumin(BSA).
As preferably, in described reagent R2, described latex is coated the preparation of anti-cardic fatty acid binding protein antibody
Method is:
With the MES buffer solution of 50 mmol/L, the polystyrene microsphere that particle diameter is 80-500nm is diluted the polyphenyl second becoming contained
The mass concentration of alkene microballoon is the solution of 1%-5%, then adds 1-ethyl-3-(the 3-dimethyl of 1.0 mg in every milliliter of solution
Amine propyl group) carbodiimide hydrochloride, react 1 hour under conditions of 20 DEG C-37 DEG C, after having reacted, use centrifuge,
It is centrifuged 30 minutes under the rotating speed of 25000 rpm/min, removes supernatant, then precipitation is carried out dilute with the MES buffer solution of 50 mmol/L
Release, use ultrasonic disperse instrument to carry out ultrasonic disperse, re-use centrifuge, be centrifuged 30 minutes under the rotating speed of 25000 rpm/min,
Remove supernatant, then precipitation is diluted with the MES buffer solution of 50 mmol/L, until the mass concentration of polystyrene microsphere is 1%-
Till 3%, add anti-cardic fatty acid binding protein antibody the most while stirring, until the mass concentration of polystyrene microsphere is
Till 0.5%-2.0%, it is eventually adding bovine serum albumin(BSA), till the concentration of bovine serum albumin(BSA) is 15 g/L, the bar of 4 DEG C
Under part, closing can prepare latex for 8-12 hour and be coated anti-cardic fatty acid binding protein antibody.
As preferably, the invention also discloses the kit of said determination cardic fatty acid binding protein preparation method and
Using method, comprises the following steps:
A () prepares reagent according to following component content:
Reagent R1:
Buffer solution 15 ~ 185 mmol/L
Surfactant 5 ~ 15 mL/L
Chelating agent 10 ~ 60 mmol/L
Preservative 0.2 ~ 0.6 g/L
Its solvent is purified water
Reagent R2:
Buffer solution 50 ~ 150 mmol/L
Inorganic ion 40 ~ 300 mmol/L
Preservative 0.2 ~ 0.6 g/L
Stabilizer 6 ~ 18 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 1 ~ 8 g/L
Its solvent is purified water；
B sample to be tested is mixed by () with reagent R1 and reagent R2 so that it is fully react；
C () measures reacted absorbance difference with automatic clinical chemistry analyzer；
D () calculates the concentration of cardic fatty acid binding protein in sample according to absorbance changing value.
As preferably, in step (b), described reagent R1 and the volume ratio of reagent R2 are 1:1；
As preferably, in step (b), described sample to be tested arrives at 1:5 with the volume ratio of reagent R1 and the cumulative volume of reagent R2
Between 1:200.
The Cleaning Principle of the present invention is: this product with latex agglutination as principle, the cardioid fat of (serum or blood plasma) in sample
Fat acid binding protein can be with the aggegation of the absorption anti-cardic fatty acid binding protein antibody generation antigen-antibody on latex particle
Reaction, forms antigen antibody complex, and the change of its turbidity, by measuring the absorbance of specific wavelength, can calculate H-FABP
Content.
Activity (the ng/mL)=C of center of a sample's type fatty acid binding protein (H-FABP)S ×(ng/mL)
In formula: the sample cell absorbance that Δ AT compares with blank tube absorbance
The calibration pipe absorbance that Δ AS compares with blank tube absorbance
The concentration of H-FABP in CS calibration solution.
Compared with prior art, the present invention has following advantageous benefits: the present invention with the addition of chelating agent in reagent R1, and
Chelating agent uses EDTA 2Na, therefore during reagent R1 and sample incubation, eliminates metal ion to doing that this detects
Disturbing, the degree of accuracy therefore measured is greatly improved, and additionally the present invention does not contains any radioactive substance, environment will not be produced dirt
Dye, and operate more convenient.
Detailed description of the invention
Further illustrate below in conjunction with specific embodiment, but the present invention is not limited in these embodiments.
Embodiment 1
The kit of the present invention includes reagent R1 independent of each other and reagent R2 biliquid component, wherein
Reagent R1:
Tris buffer solution 100 mmol/L
Tween-20 10 mL/L
EDTA·2Na 35 mmol/L
Sodium azide 0.4 g/L
Its solvent is purified water
Reagent R2:
Tris buffer solution 100 mmol/L
Sodium chloride 200 mmol/L
Sodium azide 0.4g/L
Glycerine 12 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 4 g/L
Its solvent is purified water.
Embodiment 2
The kit of the present invention includes reagent R1 independent of each other and reagent R2 biliquid component, wherein
Reagent R1:
MES buffer solution 15 mmol/L
Tween-20 15 mL/L
EDTA·2Na 10 mmol/L
Phenol 0.2 g/L
Its solvent is purified water
Reagent R2:
MES buffer solution 50 mmol/L
Magnesium chloride 300 mmol/L
Phenol 0.6 g/L
Glycerine 18 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 3g/L
Its solvent is purified water.
Embodiment 3
The preparation and application of kit
1, latex is coated the preparation of anti-cardic fatty acid binding protein antibody: with the MES buffer solution of 50 mmol/L by particle diameter be
The polystyrene microsphere dilution of 120nm becomes the solution that mass concentration is 5% of contained polystyrene microsphere, then every milliliter
Solution adds 1-ethyl-3-(3-DimethylAminopropyl) carbodiimide hydrochloride of 1.0 mg, anti-under conditions of 25 DEG C
Answer 1 hour, after having reacted, use centrifuge, be centrifuged 30 minutes under the rotating speed of 25000 rpm/min, remove supernatant, then will be heavy
Form sediment and be diluted with the MES buffer solution of 50 mmol/L, use ultrasonic disperse instrument to carry out ultrasonic disperse, re-use centrifuge,
It is centrifuged 30 minutes under the rotating speed of 25000 rpm/min, removes supernatant, then precipitation is carried out dilute with the MES buffer solution of 50 mmol/L
Release, till the mass concentration of polystyrene microsphere is 3%, adds anti-cardic fatty acid binding protein the most while stirring and resist
Body, till the mass concentration of polystyrene microsphere is 1%, is eventually adding bovine serum albumin(BSA), until bovine serum albumin(BSA)
Till concentration is 15 g/L, under conditions of 4 DEG C, closing can prepare latex for 8 hours and be coated anti-cardic fatty acid binding protein
Antibody；
2, reagent is prepared according to following component content:
Reagent R1:
Tris buffer solution 100 mmol/L
Tween-20 10 mL/L
EDTA·2Na 35 mmol/L
Sodium azide 0.4 g/L
Its solvent is purified water
Reagent R2:
Tris buffer solution 100 mmol/L
Sodium chloride 200 mmol/L
Sodium azide 0.4g/L
Glycerine 12 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 4 g/L
Its solvent is purified water；
3, automatic clinical chemistry analyzer parameter is arranged
(a) detection temperature: 37 DEG C；
(b) detection wavelength: dominant wavelength 700nm；
(c) reaction time: 10min, wherein, incubation time 5min, measure immediately after adding reagent R2 and read absorbance
Read absorbance A 2 after A1,5min, calculate absorbance changes delta A=A2-A1；
(d) the Direction of Reaction: positive reaction；
4, detecting step
A () takes 100 μ l reagent R1 and the mixing of 4 μ l samples to be tested；
B solution after mixing is hatched 5min under conditions of 37 DEG C by ()；
C () adds 100 μ l reagent R2, measure immediately and read absorbance A 1, reads absorbance A 2 after 5min, calculates absorbance change
Δ A=A2-A1；
D () is according to activity (the ng/mL)=C of the cardic fatty acid binding protein (H-FABP) in sampleS × (ng/mL)
Calculate the concentration of cardic fatty acid binding protein in sample.
Embodiment 4
The preparation and application of kit
1, latex is coated the preparation of anti-cardic fatty acid binding protein antibody: with the MES buffer solution of 50 mmol/L by particle diameter be
The polystyrene microsphere dilution of 120nm becomes the solution that mass concentration is 5% of contained polystyrene microsphere, then every milliliter
Solution adds 1-ethyl-3-(3-DimethylAminopropyl) carbodiimide hydrochloride of 1.0 mg, anti-under conditions of 25 DEG C
Answer 1 hour, after having reacted, use centrifuge, be centrifuged 30 minutes under the rotating speed of 25000 rpm/min, remove supernatant, then will be heavy
Form sediment and be diluted with the MES buffer solution of 50 mmol/L, use ultrasonic disperse instrument to carry out ultrasonic disperse, re-use centrifuge,
It is centrifuged 30 minutes under the rotating speed of 25000 rpm/min, removes supernatant, then precipitation is carried out dilute with the MES buffer solution of 50 mmol/L
Release, till the mass concentration of polystyrene microsphere is 3%, adds anti-cardic fatty acid binding protein the most while stirring and resist
Body, till the mass concentration of polystyrene microsphere is 1%, is eventually adding bovine serum albumin(BSA), until bovine serum albumin(BSA)
Till concentration is 15 g/L, under conditions of 4 DEG C, closing can prepare latex for 8 hours and be coated anti-cardic fatty acid binding protein
Antibody；
2, reagent is prepared according to following component content:
Reagent R1:
MES buffer solution 15 mmol/L
Tween-20 15 mL/L
EDTA·2Na 10 mmol/L
Phenol 0.2 g/L
Its solvent is purified water
Reagent R2:
MES buffer solution 50 mmol/L
Magnesium chloride 300 mmol/L
Phenol 0.6 g/L
Glycerine 18 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 3g/L
Its solvent is purified water；
3, automatic clinical chemistry analyzer parameter is arranged
(a) detection temperature: 37 DEG C；
(b) detection wavelength: dominant wavelength 700nm；
(c) reaction time: 10min, wherein, incubation time 5min, measure immediately after adding reagent R2 and read absorbance
Read absorbance A 2 after A1,5min, calculate absorbance changes delta A=A2-A1；
(d) the Direction of Reaction: positive reaction；
4, detecting step
A () takes 100 μ l reagent R1 and the mixing of 4 μ l samples to be tested；
B solution after mixing is hatched 5min under conditions of 37 DEG C by ()；
C () adds 100 μ l reagent R2, measure immediately and read absorbance A 1, reads absorbance A 2 after 5min, calculates absorbance change
Δ A=A2-A1；
D () is according to activity (the ng/mL)=C of the cardic fatty acid binding protein (H-FABP) in sampleS × (ng/mL)
Calculate the concentration of cardic fatty acid binding protein in sample.
Obtained by the kit of the table 1 mensuration cardic fatty acid binding protein obtained by embodiment 1 and embodiment 2
Measure the result that quality-control product 1 is measured by the kit of cardic fatty acid binding protein respectively, the wherein cardioid in quality-control product 1
The concentration of fatty acid binding protein is 6 ng/mL, and measurement result is shown in Table 1:
Table 1
| 1st time (ng/mL) | 2nd time (ng/mL) | 3rd time (ng/mL) | Average (ng/mL) | Deviation (%) | |
| Embodiment 1 | 6 | 6 | 6 | 6 | 0.00 |
| Embodiment 2 | 6 | 5 | 6 | 5.67 | 5.56 |
As shown in Table 1, the measurement result to quality-control product 1 of the kit measuring cardic fatty acid binding protein obtained by the present invention
Deviation is less, and therefore accuracy of measurement is high, and embodiment 1 is optimum selection.
The table 2 kit measuring cardic fatty acid binding protein obtained by embodiment 1 and the mensuration obtained by embodiment 2
The result that quality-control product 2 is measured by the kit of cardic fatty acid binding protein respectively, the wherein fat of the cardioid in quality-control product 2
The concentration of acid binding protein is 30 ng/mL, and measurement result is shown in Table 2:
Table 2
| 1st time (ng/mL) | 2nd time (ng/mL) | 3rd time (ng/mL) | Average (ng/mL) | Deviation (%) | |
| Embodiment 1 | 31 | 30 | 30 | 30.3 | 1.00 |
| Embodiment 2 | 32 | 31 | 31 | 31.3 | 4.33 |
As shown in Table 2, the measurement result to quality-control product 2 of the kit measuring cardic fatty acid binding protein obtained by the present invention
Deviation is less, and therefore accuracy of measurement is high, and embodiment 1 is optimum selection.
Same sample to be tested is carried out by the table 3 kit measuring cardic fatty acid binding protein obtained by embodiment 3
Be repeatedly repeatedly measured and obtained by embodiment 4 measure cardic fatty acid binding protein kit to same sample to be tested
Carry out is repeatedly repeatedly measured, and the result of gained carries out the calculating of SD and CV, and result is as follows:
Table 3
The precision of the kit measuring cardic fatty acid binding protein obtained by the present invention is relatively good as shown in Table 3, and
As shown in Table 3, embodiment 3 is optimum selection.
The principle of above-described embodiment only illustrative present invention and effect thereof, not for limiting the present invention.Any ripe
Above-described embodiment all can be modified under the spirit and the scope of the present invention or change by the personage knowing this technology.Cause
This, have usually intellectual such as complete with institute under technological thought without departing from disclosed spirit in art
All equivalences become are modified or change, and must be contained by the claim of the present invention.
Claims (8)
1. the kit measuring cardic fatty acid binding protein, it is characterised in that: include reagent R1 independent of each other and examination
Agent R2 biliquid component, including composition and corresponding content be:
Reagent R1:
Buffer solution 15 ~ 185 mmol/L
Surfactant 5 ~ 15 mL/L
Chelating agent 10 ~ 60 mmol/L
Preservative 0.2 ~ 0.6 g/L
Its solvent is purified water
Reagent R2:
Buffer solution 50 ~ 150 mmol/L
Inorganic ion 40 ~ 300 mmol/L
Preservative 0.2 ~ 0.6 g/L
Stabilizer 6 ~ 18 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 1 ~ 8 g/L
Its solvent is purified water.
A kind of kit measuring cardic fatty acid binding protein the most according to claim 1, it is characterised in that: include that
This independent reagent R1 and reagent R2 biliquid component, including composition and corresponding content be:
Reagent R1:
Buffer solution 100 mmol/L
Surfactant 10 mL/L
Chelating agent 35 mmol/L
Preservative 0.4 g/L
Its solvent is purified water
Reagent R2:
Buffer solution 100 mmol/L
Inorganic ion 200 mmol/L
Preservative 0.4g/L
Stabilizer 12 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 4 g/L
Its solvent is purified water.
A kind of kit measuring cardic fatty acid binding protein the most according to claim 1 and 2, it is characterised in that: institute
In the reagent R1 stated, described buffer solution uses in Tris buffer solution, MES buffer solution, MOPSO buffering, glycine buffer
The combination of one or more, described surfactant uses Tween-20, described chelating agent to use EDTA 2Na, described
Preservative uses the combination of one or more in Sodium azide, Proclin-300, phenol.
A kind of kit measuring cardic fatty acid binding protein the most according to claim 1 and 2, it is characterised in that: institute
In the reagent R2 stated, described buffer solution uses in Tris buffer solution, MES buffer solution, MOPSO buffering, glycine buffer
One or more combinations, described inorganic ion uses the combination of one or more in sodium chloride, magnesium chloride, potassium chloride,
Described preservative uses the combination of one or more in Sodium azide, Proclin-300, phenol, described stabilizer to use
The combination of one or more in sucrose, glycerine, bovine serum albumin(BSA).
A kind of kit measuring cardic fatty acid binding protein the most according to claim 1 and 2, it is characterised in that: institute
In the reagent R2 stated, described latex is coated the preparation method of anti-cardic fatty acid binding protein antibody and is: with 50 mmol/L's
The polystyrene microsphere dilution that particle diameter is 80-500nm is become the mass concentration of contained polystyrene microsphere by MES buffer solution
The solution of 1%-5%, then adds 1-ethyl-3-(3-DimethylAminopropyl) carbodiimides of 1.0 mg in every milliliter of solution
Hydrochloride, reacts 1 hour under conditions of 20 DEG C-37 DEG C, after having reacted, uses centrifuge, turning at 25000 rpm/min
Lower centrifugal 30 minutes of speed, removes supernatant, then precipitation is diluted with the MES buffer solution of 50 mmol/L, uses ultrasonic disperse instrument to enter
Row ultrasonic disperse, re-uses centrifuge, is centrifuged 30 minutes, removes supernatant under the rotating speed of 25000 rpm/min, then by precipitation with 50
The MES buffer solution of mmol/L is diluted, till the mass concentration of polystyrene microsphere is 1%-3%, the most while stirring
Add anti-cardic fatty acid binding protein antibody, till the mass concentration of polystyrene microsphere is 0.5%-2.0%, finally add
Enter bovine serum albumin(BSA), till the concentration of bovine serum albumin(BSA) is 15 g/L, close 8-12 hour under conditions of 4 DEG C
Prepare latex and be coated anti-cardic fatty acid binding protein antibody.
The preparation method of a kind of kit measuring cardic fatty acid binding protein the most according to claim 1 and 2 and making
By method, it is characterised in that: comprise the following steps:
A () prepares reagent according to following component content:
Reagent R1:
Buffer solution 15 ~ 185 mmol/L
Surfactant 5 ~ 15 mL/L
Chelating agent 10 ~ 60 mmol/L
Preservative 0.2 ~ 0.6 g/L
Its solvent is purified water
Reagent R2:
Buffer solution 50 ~ 150 mmol/L
Inorganic ion 40 ~ 300 mmol/L
Preservative 0.2 ~ 0.6 g/L
Stabilizer 6 ~ 18 g/L
Latex is coated anti-cardic fatty acid binding protein antibody 1 ~ 8 g/L
Its solvent is purified water；
B sample to be tested is mixed by () with reagent R1 and reagent R2 so that it is fully react；
C () measures reacted absorbance difference with automatic clinical chemistry analyzer；
D () calculates the concentration of cardic fatty acid binding protein in sample according to absorbance changing value.
The preparation method of a kind of kit measuring cardic fatty acid binding protein the most according to claim 6 and user
Method, it is characterised in that: in step (b), described reagent R1 and the volume ratio of reagent R2 are 1:1.
The preparation method of a kind of kit measuring cardic fatty acid binding protein the most according to claim 6 and user
Method, it is characterised in that: in step (b), described sample to be tested arrives at 1:5 with the volume ratio of reagent R1 and the cumulative volume of reagent R2
Between 1:200.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610358106.8A CN105929176A (en) | 2016-05-26 | 2016-05-26 | Kit for determining heart-type fatty acid binding protein and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610358106.8A CN105929176A (en) | 2016-05-26 | 2016-05-26 | Kit for determining heart-type fatty acid binding protein and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105929176A true CN105929176A (en) | 2016-09-07 |
Family
ID=56842303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610358106.8A Pending CN105929176A (en) | 2016-05-26 | 2016-05-26 | Kit for determining heart-type fatty acid binding protein and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105929176A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109142749A (en) * | 2018-08-11 | 2019-01-04 | 金华市强盛生物科技有限公司 | A kind of cardic fatty acid binding protein detection kit |
| CN111272991A (en) * | 2020-01-21 | 2020-06-12 | 苏州德沃生物技术有限公司 | Antigen stabilizing agent |
| CN112630430A (en) * | 2020-11-16 | 2021-04-09 | 北京美联泰科生物技术有限公司 | Kit for quantitatively detecting UCHL-1 and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102628864A (en) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | Kit for determining heart-type fatty acid binding protein in serum or urine by latex enhanced turbidimetric immunoassay |
| CN102788880A (en) * | 2012-08-16 | 2012-11-21 | 北京恩济和生物科技有限公司 | Heart-type fatty acid binding protein detection reagent kit and preparation method thereof |
| CN103123319A (en) * | 2012-12-20 | 2013-05-29 | 武汉生之源生物科技有限公司 | Heart-type fatty acid binding protein content detection kit and preparation method thereof |
| CN104215772A (en) * | 2014-08-14 | 2014-12-17 | 上海睿康生物科技有限公司 | Heart-type fatty acid binding protein detection kit and making method thereof |
| CN104726412A (en) * | 2014-12-19 | 2015-06-24 | 湖南师范大学 | Monoclonal antibody specifically combined with HFABP (heart fatty acid binding protein) and applications thereof |
-
2016
- 2016-05-26 CN CN201610358106.8A patent/CN105929176A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102628864A (en) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | Kit for determining heart-type fatty acid binding protein in serum or urine by latex enhanced turbidimetric immunoassay |
| CN102788880A (en) * | 2012-08-16 | 2012-11-21 | 北京恩济和生物科技有限公司 | Heart-type fatty acid binding protein detection reagent kit and preparation method thereof |
| CN103123319A (en) * | 2012-12-20 | 2013-05-29 | 武汉生之源生物科技有限公司 | Heart-type fatty acid binding protein content detection kit and preparation method thereof |
| CN104215772A (en) * | 2014-08-14 | 2014-12-17 | 上海睿康生物科技有限公司 | Heart-type fatty acid binding protein detection kit and making method thereof |
| CN104726412A (en) * | 2014-12-19 | 2015-06-24 | 湖南师范大学 | Monoclonal antibody specifically combined with HFABP (heart fatty acid binding protein) and applications thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109142749A (en) * | 2018-08-11 | 2019-01-04 | 金华市强盛生物科技有限公司 | A kind of cardic fatty acid binding protein detection kit |
| CN111272991A (en) * | 2020-01-21 | 2020-06-12 | 苏州德沃生物技术有限公司 | Antigen stabilizing agent |
| CN112630430A (en) * | 2020-11-16 | 2021-04-09 | 北京美联泰科生物技术有限公司 | Kit for quantitatively detecting UCHL-1 and application thereof |
| CN112630430B (en) * | 2020-11-16 | 2021-08-27 | 北京美联泰科生物技术有限公司 | Kit for quantitatively detecting UCHL-1 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102628864B (en) | Kit for determining heart-type fatty acid binding protein in serum or urine by latex enhanced turbidimetric immunoassay | |
| CN106093422A (en) | A kind of test kit measuring neutrophil gelatinase-associated lipocalin NGAL | |
| CN106093407A (en) | A kind of test kit measuring lipoprotein (a) and preparation method thereof | |
| CN103852584B (en) | A kind of latex enhancing immune of quantitative detection C peptide is than turbid kit | |
| CN106018852B (en) | For analyzing the individuation quality controls object of test | |
| CN106198961A (en) | The latex of a kind of detection by quantitative serum amyloid A protein strengthens Immunoturbidimetric kit and preparation method thereof | |
| JPS5825980B2 (en) | Cyclic nucleotide quantification method | |
| CN106093418A (en) | A kind of test kit measuring Troponin I and preparation method thereof | |
| CN105929177A (en) | Kit for determining anti-cyclic citrullinated peptide and preparation method thereof | |
| US8153594B2 (en) | Tacrolimus standard and methods of using same | |
| CN106018299A (en) | Kit for measuring serum amyloid A and preparation method of kit | |
| CN107656069A (en) | Full-range C reactive protein quantitative detecting reagent and method in whole blood | |
| CN105929176A (en) | Kit for determining heart-type fatty acid binding protein and preparation method thereof | |
| CN106483282A (en) | A kind of antigen stabilizer and preparation method and application | |
| CN106501536A (en) | A kind of latex orientation coupling technology detection lipoprotein（a）Test kit | |
| CN108169145A (en) | A kind of kit for measuring serum complement C1q and its preparation application method | |
| CN106086161A (en) | A kind of lipoprotein phospholipase A2 detectable and preparation thereof and using method | |
| CN103743911B (en) | A kind of fibronectin determination kit and preparation method thereof | |
| CN106053838A (en) | Kit for determining transferrin and preparation method thereof | |
| CN106053840A (en) | Kit for measuring alpha1-microglobulin and preparation method of kit | |
| CN110596405A (en) | Kit for detecting content of heart-type fatty acid binding protein by latex enhanced immunoturbidimetry | |
| CN105988003B (en) | A kind of whole process c reactive protein assay kit and its application | |
| CN106093425A (en) | A kind of test kit measuring antikeratin antibody and preparation method thereof | |
| CN106353505B (en) | ApoE kits based on catalyzed signal amplification | |
| CN106053828A (en) | Kit for measuring full-measuring-range-C reactive protein and preparation method of kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160907 |